3691 - 3700 of 9148 Results
Title
Year
-
OPENTitle: Discovery and characterization of N-(1,3-dialkyl-1H-indazol-6-yl)-1H-pyrazolo[4,3-b]pyridin-3-amine scaffold as mGlu4 positive allosteric modulators that mitigate CYP1A2 induction liabilityJournal Name: Bioorganic & Medicinal Chemistry LettersPublisher: Elsevier BVVol: 28Issue #: 15Start Page: 2641End Page: 2646Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.bmcl.2018.06.034Best OA location URL: https://doi.org/10.7270/q2dr2z5hCitation Count: 14
-
OPENTitle: The future of clinical trials? Monitoring mobility as an outcome measure in Parkinson's disease: The mobilise-D studyJournal Name: Journal of Parkinson’s DiseasePublisher: SAGE PublicationsVol: 16Issue #: 1Start Page: 110End Page: 124Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1177/1877718x251407026Best OA location URL: https://doi.org/10.1177/1877718x251407026Citation Count: 4
- High priority publications on Parkinson's disease in 20172017RESTRICTEDTitle: High priority publications on Parkinson's disease in 2017Journal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 17Issue #: 1Start Page: 8End Page: 10Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(17)30416-7Citation Count: 0
- In Situ Global Structural Proteome Analysis Identifies Potential Biomarkers for Parkinson's Disease2023OPENTitle: In Situ Global Structural Proteome Analysis Identifies Potential Biomarkers for Parkinson's DiseaseJournal Name: Movement DisordersPublisher: WileyVol: 38Issue #: 2Start Page: 198End Page: 198Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1002/mds.29315Best OA location URL: https://doi.org/10.1002/mds.29315Citation Count: 2
-
OPENTitle: Dissecting the Binding Profile of PET Tracers to Corticobasal Degeneration Tau FibrilsJournal Name: ACS Chemical NeurosciencePublisher: American Chemical Society (ACS)Vol: 12Issue #: 18Start Page: 3487End Page: 3496Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1021/acschemneuro.1c00536Best OA location URL: https://pubs.acs.org/doi/pdf/10.1021/acschemneuro.1c00536Citation Count: 24
- Nanoparticle standards for immuno-based quantitation of α-synuclein oligomers in diagnostics of Parkinson's disease and other synucleinopathies2017RESTRICTEDTitle: Nanoparticle standards for immuno-based quantitation of α-synuclein oligomers in diagnostics of Parkinson's disease and other synucleinopathiesJournal Name: Clinica Chimica ActaPublisher: Elsevier BVVol: 466Issue #:Start Page: 152End Page: 159Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.cca.2017.01.010Citation Count: 30
-
OPENTitle: Impaired contrast sensitivity is associated with more severe cognitive impairment in Parkinson diseaseJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 34Issue #:Start Page: 15End Page: 19Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2016.10.006Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/5222688Citation Count: 40
-
OPENTitle: A high-content imaging workflow to screen for molecules that reduce cellular uptake of α-synuclein preformed fibrilsJournal Name: MethodsPublisher: Elsevier BVVol: 252Issue #:Start Page: 41End Page: 54Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.ymeth.2026.05.001Best OA location URL: https://doi.org/10.1016/j.ymeth.2026.05.001Citation Count: 0
-
OPENTitle: Fyn Knock-Down Prevents Levodopa-Induced Dyskinesia in a Mouse Model of Parkinson’s DiseaseJournal Name: eneuroPublisher: Society for NeuroscienceVol: 8Issue #: 4Start Page: ENEURO.0559End Page: 20.2021Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1523/eneuro.0559-20.2021Best OA location URL: https://www.eneuro.org/content/eneuro/8/4/ENEURO.0559-20.2021.full.pdfCitation Count: 14
-
OPENTitle: Targeting Rab‐RILPL interactions as a strategy to downregulate pathogenic LRRK2 in Parkinson's diseaseJournal Name: Journal of Peptide SciencePublisher: WileyVol: 30Issue #: 5Start Page: e3563End Page: e3563Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1002/psc.3563Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/psc.3563Citation Count: 4